Nektar Reports Preclinical Data Presented at AACR, Showed Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition

By: via Benzinga
Nektar Therapeutics (NASDAQ: NKTR) today announced new preclinical data for the company's investigational immuno-stimulatory cytokine ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.